However, prolongation of the QTc interval in women with HER2-negative breast cancer undergoing the specific chemotherapy treatment regimen of doxorubicin, cyclophosphamide, and paclitaxel has never been studied until now. Here, ERBB2 is linked to breast carcinoma.